Tirzepatide in Canada: A Complete Research Guide

Canadian searches for "tirzepatide Canada" have climbed steadily for two years. Part of that is the drug itself. Mounjaro arrived in Canadian pharmacies in late 2022, Zepbound followed for obesity, and the SURMOUNT-5 readout in May 2025 settled the long-running head-to-head question with semaglutide in favour of tirzepatide at matched exposure. The other part is price. At roughly four hundred fifty to six hundred Canadian dollars a month retail and uneven provincial and private coverage, branded tirzepatide remains out of reach for many of the Canadians who want it. A parallel research channel has grown to meet that gap, operating under the unauthorised-drug framework Health Canada applies to non-DIN peptides. This guide is written for Canadian researchers working in that channel.

Northern Compound is an editorially independent publication. Nothing written here is medical advice. The intent is to give anyone studying tirzepatide in Canada a grounded, readable reference that holds up when the protocol meets the bench: what the molecule is, how it was designed, how it performed in SURPASS and SURMOUNT, how to reconstitute and store it, and how to evaluate a supplier when most of the industry is based abroad.

When the reader is ready to compare live research-supply routes, move from this mechanism guide to the GLP-1 peptide buyer's checklist for Canadian research materials. That page keeps dual GIP/GLP-1 sourcing separate from GLP-1-only, triple-agonist, and amylin-pathway questions, then routes the file through batch-level COA review, identity confirmation, storage notes, and RUO claim screening before any ProductLink click.

What tirzepatide is#

Tirzepatide is a synthetic thirty-nine amino acid peptide. Its sequence is a modified version of native glucose-dependent insulinotropic polypeptide, better known as GIP. Eli Lilly's medicinal chemistry team began with the GIP backbone and rewrote nine residues to introduce simultaneous affinity for the glucagon-like peptide-1 receptor. The result is a single molecule that binds and activates two receptors that the body normally uses in parallel after a meal.

The molecule is not a straight copy of any native hormone. Position two carries an alpha-aminoisobutyric acid, an unnatural amino acid that resists cleavage by dipeptidyl peptidase-4, the enzyme that inactivates native GIP and GLP-1 within minutes in circulation. Position twenty is modified with a lysine carrying a gamma-glutamate linker and a C20 fatty diacid tail. That fatty side chain binds serum albumin reversibly. Bound to albumin, tirzepatide is protected from renal clearance and extends its effective plasma half-life from the minutes that characterise native incretins to roughly one hundred twenty hours in human subjects. That half-life supports the once-weekly dosing cadence used across every published trial.

The literature sometimes refers to tirzepatide as a "twincretin". The word is informal but captures the design philosophy. Native GIP and GLP-1 are released by intestinal K and L cells respectively in response to nutrient absorption. They work together in healthy postprandial physiology to potentiate insulin release, suppress glucagon, delay gastric emptying, and signal satiety. Tirzepatide recruits both arms of that response from a single injection. Researchers exploring metabolic pathways, appetite signalling, and glucose handling now routinely include tirzepatide alongside older reference compounds in comparative work.

The molecular weight is 4,813.5 daltons. The isoelectric point sits around 5.1. The peptide is soluble in aqueous buffers at neutral to slightly alkaline pH and is supplied by research vendors as a white lyophilised cake. A typical research vial carries ten or thirty milligrams of active peptide with negligible excipient, meant to be reconstituted by the end user rather than arriving as a ready-to-inject pen.

How tirzepatide was developed#

The design rationale behind tirzepatide is worth understanding because it pushes back against a widely held assumption. For most of the 2000s and 2010s, the field considered GIP agonism a metabolic dead end. Early rodent work suggested that in type 2 diabetes the GIP receptor response was blunted, and some human studies found that exogenous GIP did little in diabetic subjects. That view steered development toward GLP-1 mono agonism for a decade. Exenatide, liraglutide, dulaglutide, and semaglutide all followed that path.

Eli Lilly's team reopened the question in the mid 2010s. Their hypothesis was that the GIP resistance seen in type 2 diabetes might be a consequence of hyperglycaemia rather than a fixed defect. If glycaemic control could be restored, GIP signalling might be rescued alongside it. A peptide that carried both activities might then access the full incretin axis rather than half of it. The LY3298176 programme, which became tirzepatide, was designed to test that idea in the clinic.

Phase 1 single-ascending-dose work ran in 2017 and 2018. The pharmacokinetic profile matched prediction. The safety signal was clean enough at the exposures used. Phase 2 data published in 2019 showed outsize weight and HbA1c effects relative to the mono GLP-1 agonist comparator. The signal survived into a pivotal Phase 3 programme, which Lilly split into two parallel trial families. SURPASS covered type 2 diabetes. SURMOUNT covered obesity. Regulatory approval followed in a cascade. The United States Food and Drug Administration approved tirzepatide for type 2 diabetes in May 2022. Health Canada followed in November 2022, authorising the brand name Mounjaro. European approval came in September 2022. The obesity indication, marketed as Zepbound in the United States and approved in Canada in the months following the SURMOUNT readouts, arrived in 2023 and 2024.

The development arc did something the field had not fully expected. It rehabilitated GIP as a viable pharmacological target and created a new molecular class. Within eighteen months of tirzepatide approval, at least four other dual and triple incretin agonists were in active clinical development, with retatrutide the most prominent example.

GIP and GLP-1 receptor biology, and why dual agonism matters#

The two receptors tirzepatide recruits sit on different tissues and produce overlapping but non-identical downstream effects. Understanding both is the difference between reading the trial data well and reading it poorly.

The GLP-1 receptor#

GLP-1 is secreted by L cells in the distal small intestine and colon in response to nutrient sensing. Its receptor, GLP-1R, is a class B G-protein-coupled receptor expressed on pancreatic beta cells, on neurons in the hypothalamus and hindbrain, on cells of the gastrointestinal tract, and at lower density on cardiovascular tissue. Receptor activation recruits Gs, raises cyclic AMP, and produces a family of effects that the diabetes field has characterised in detail over twenty years of work with exenatide and its successors.

On beta cells the effect is glucose-dependent insulin secretion. GLP-1R activation amplifies the first-phase insulin response to rising glucose but does not drive insulin release at normoglycaemia, which is why GLP-1 class agents rarely cause hypoglycaemia on their own. On alpha cells the same pathway suppresses glucagon release. On enteric neurons the receptor slows gastric emptying, which flattens the postprandial glucose excursion and extends the sense of fullness. On hypothalamic and brainstem neurons the receptor produces satiety and reduces food intake. These are the effects that made GLP-1 mono agonism a successful therapeutic class.

The GIP receptor#

GIP is secreted by K cells in the proximal duodenum and jejunum in response to nutrient absorption, especially fat and glucose. Its receptor, GIP-R, is also a class B GPCR but it distributes differently. Beta cells express it. Adipocytes express it at high density. Bone expresses it. Specific populations of hypothalamic and hindbrain neurons express it. Cardiac tissue expresses it at lower levels.

On beta cells in healthy physiology GIP is actually the more important of the two incretins for postprandial insulin release, contributing roughly sixty percent of the incretin effect after a mixed meal. In overt type 2 diabetes that response is blunted, which is the finding that pushed the field away from GIP agonism for a decade. Tirzepatide's clinical behaviour suggests that the blunting is at least partly reversible.

On adipocytes the GIP receptor has a more complicated story. In healthy weight it supports fat storage and lipoprotein lipase activity. In the context of combined GIP and GLP-1 agonism at pharmacological exposure it produces a catabolic signature, with improvements in insulin sensitivity and apparent reductions in ectopic fat. The mechanistic literature is still being written. The SURPASS-3 MRI substudy, among others, found reductions in liver fat and visceral adipose tissue that exceeded what GLP-1 mono therapy produces at matched weight loss, suggesting an adipose-specific effect beyond net energy balance.

On hypothalamic neurons GIP receptor activation produces satiety signals that are additive to GLP-1 effects, engaging different circuits. This is one of the proposed reasons that SURMOUNT weight-loss numbers exceed semaglutide results.

The receptor affinity question#

A persistent point of confusion is the receptor affinity ratio. Tirzepatide is often described as five times more potent at GIP than at GLP-1. That statement is partly true and partly oversimplified. In binding assays tirzepatide has high affinity for GIP-R, comparable to native GIP. Its affinity for GLP-1R is lower than native GLP-1, roughly an order of magnitude weaker in some assay systems. In functional cAMP readouts the pattern is similar: tirzepatide is a full agonist at GIP-R and a biased partial agonist at GLP-1R, with preferential cAMP signalling over beta-arrestin recruitment. That biased signalling at GLP-1R is theorised to contribute to the tolerability profile, reducing receptor internalisation and tachyphylaxis.

The practical consequence is that tirzepatide behaves in vivo as if it were a strong GIP agonist and a moderate GLP-1 agonist, not as twice a GLP-1 drug. Researchers comparing tirzepatide to semaglutide at equipotent GLP-1 exposures find that tirzepatide's incremental effects ride on the GIP arm, not on GLP-1 over-agonism.

The SURPASS trial programme#

SURPASS covered type 2 diabetes across five primary trials, one Asian Pacific extension, and multiple sub-studies. The programme enrolled roughly thirteen thousand participants across a mix of populations that had previously been studied with GLP-1 mono agonists.

SURPASS-1 was the monotherapy study. Four hundred seventy-eight adults with type 2 diabetes inadequately controlled by diet and exercise received tirzepatide at five, ten, or fifteen milligrams weekly or placebo for forty weeks. HbA1c reductions were 1.87, 1.89, and 2.07 percent at the three active doses. Placebo moved 0.04 percent. Weight losses ranged from 7.0 to 9.5 kilograms at the highest dose. Roughly eighty-five percent of participants reached an HbA1c under 7.0 percent on fifteen milligrams.

SURPASS-2 was the head-to-head with semaglutide. It enrolled 1,879 adults with type 2 diabetes on metformin and compared tirzepatide 5, 10, or 15 mg weekly against semaglutide 1 mg weekly over forty weeks. Tirzepatide beat semaglutide on every prespecified endpoint. HbA1c reduction was 2.01, 2.24, and 2.30 percent for the tirzepatide arms versus 1.86 percent for semaglutide. Weight loss was 7.6, 9.3, and 11.2 kilograms versus 5.7 kilograms. The safety profile was broadly similar across arms, with GI events highest in the highest tirzepatide arm.

SURPASS-3 studied tirzepatide against insulin degludec in insulin-naive patients. Fifty-two weeks of tirzepatide produced HbA1c reductions of 1.93 to 2.37 percent with weight losses of 7.5 to 12.9 kilograms. Insulin degludec produced similar glycaemic control but weight gain of 2.3 kilograms on average.

SURPASS-4 added the cardiovascular risk dimension. It enrolled 2,002 participants with elevated CV risk and ran against insulin glargine. Over fifty-two weeks of dose titration and follow-up, tirzepatide produced glycaemic and weight outcomes that exceeded glargine while keeping major adverse cardiovascular event rates numerically lower. The trial was not powered as a cardiovascular outcomes trial, but the results were reassuring enough to support progression into SURPASS-CVOT.

SURPASS-5 examined tirzepatide as add-on to insulin glargine. SURPASS-AP-Combo ran in Asian populations where type 2 diabetes phenotypes often differ from Western cohorts. SURPASS-J extended to Japanese participants. Across the programme the HbA1c signal was remarkably consistent: roughly 2.0 to 2.5 percent reductions at fifteen milligrams, with weight losses of seven to thirteen kilograms even in non-obese diabetic populations.

The SURMOUNT trial programme#

SURMOUNT covered obesity without diabetes and is the programme that drove most of the public conversation about tirzepatide. It enrolled a broader, larger population than SURPASS.

SURMOUNT-1 published in the New England Journal of Medicine in July 2022 was the foundational trial. It enrolled 2,539 adults with obesity or overweight with at least one comorbidity, excluding diabetes. Over seventy-two weeks participants received tirzepatide at five, ten, or fifteen milligrams weekly with titration or placebo. Mean weight reduction from baseline was 15.0 percent on five milligrams, 19.5 percent on ten milligrams, and 20.9 percent on fifteen milligrams. Placebo moved 3.1 percent. Of participants on fifteen milligrams, 36.2 percent lost more than twenty-five percent of baseline weight. The result was the largest weight-loss signal ever published for a non-surgical intervention.

SURMOUNT-2 ran in adults with both obesity and type 2 diabetes, a population historically harder to treat for weight loss. Seventy-two weeks of tirzepatide produced 13.4 and 15.7 percent weight reduction at ten and fifteen milligrams, versus 3.3 percent on placebo. The numbers were lower than SURMOUNT-1 but still substantially above anything previously achieved in this population.

SURMOUNT-3 examined intensive lifestyle intervention as a lead-in. Participants completed twelve weeks of lifestyle therapy, losing roughly seven percent of body weight, then were randomised to tirzepatide or placebo for a further seventy-two weeks. Tirzepatide produced an additional 18.4 percent weight loss on top of lifestyle losses, for a total of roughly twenty-six percent. Placebo subjects regained weight.

SURMOUNT-4 tested withdrawal. After thirty-six weeks of open-label tirzepatide during which participants lost an average of 20.9 percent of baseline weight, participants were randomised to continued tirzepatide or placebo for fifty-two weeks. The continued-treatment arm lost an additional 5.5 percent. The placebo arm regained 14.0 percent of lost weight. The trial established that discontinuation without a maintenance strategy produces rapid and substantial regain, a finding that has shaped how researchers think about cessation design in this class.

SURMOUNT-5 was the direct head-to-head with semaglutide 2.4 mg, the approved obesity dose. The trial enrolled 751 participants with obesity without diabetes and ran for seventy-two weeks. Mean weight reduction was 20.2 percent on tirzepatide versus 13.7 percent on semaglutide. Tirzepatide was superior on every prespecified secondary endpoint including percentage of participants reaching ten, fifteen, twenty, and twenty-five percent weight reduction. The safety profiles were similar with GI events somewhat higher on tirzepatide. SURMOUNT-5 was the first adequately powered head-to-head in the GLP-1 obesity class and it settled the potency question decisively.

Comparing tirzepatide to semaglutide at matched timepoints#

Because SURMOUNT-5 and SURPASS-2 both used semaglutide as an active comparator, the literature now has rare like-for-like data. The comparisons matter because most Canadian researchers reading this guide are choosing between semaglutide and tirzepatide for their study design.

A few notes on reading that table honestly. SURPASS-2 used semaglutide 1 mg, which is the approved T2D dose, not the 2.4 mg obesity dose. SURMOUNT-5 corrected for that by using 2.4 mg semaglutide. The obesity comparison in SURMOUNT-5 is therefore the cleaner benchmark. Second, the numbers above are means. Responder distribution matters. About thirty-six percent of SURMOUNT-1 participants on fifteen milligrams tirzepatide exceeded twenty-five percent weight loss. That tail behaviour is not captured by means and is part of why researchers who care about extreme responders are increasingly turning to tirzepatide.

The head-to-head does not imply tirzepatide is always the better choice for every study. Semaglutide has a larger real-world evidence base, a cardiovascular outcomes trial that has already reported favourably, and a longer exposure history. For a research programme that prioritises generalisability of findings to the most widely-used compound, semaglutide remains the reference. For a study prioritising maximum effect size or the contribution of GIP agonism specifically, tirzepatide is the compound of interest.

Pharmacokinetics and dose titration#

The tirzepatide dose schedule used across trials is 2.5 milligrams weekly for four weeks, then 5 milligrams weekly for four weeks, then incremental increases of 2.5 milligrams every four weeks until either the maintenance dose is reached or side effects require a pause. Maintenance doses studied were 5, 10, and 15 milligrams in type 2 diabetes, with 15 milligrams the highest dose carried in SURMOUNT. Some extended-access protocols use a slower titration of eight weeks per step for participants with persistent gastrointestinal symptoms.

The 2.5 milligram starting dose is not intended to be therapeutic. It is a tolerance-building step. Weight and HbA1c effects at 2.5 milligrams are modest and inconsistent across trials. Researchers running short protocols that start and stop at 2.5 milligrams should expect little signal.

Subcutaneous bioavailability is approximately eighty percent. Time to peak plasma concentration is twenty-four to seventy-two hours after injection. The plasma half-life of roughly five to six days supports once-weekly dosing and produces steady state by approximately the fourth week at any given dose. Trough-to-peak ratios are relatively flat within a dosing interval, which is part of what makes the tolerability at steady state better than initial titration. Participants who complete titration tend to report that nausea peaks during titration steps and subsides once a dose is held.

Bioavailability is similar across injection sites. Trial protocols allowed abdominal, thigh, and upper arm administration. No meaningful PK differences have been reported across sites. Some protocols require rotation of injection sites within the allowed regions to reduce local reactions.

Pharmacokinetics are not meaningfully affected by moderate hepatic or renal impairment. The fatty diacid side chain ties clearance largely to albumin handling and proteolytic degradation rather than hepatic or renal pathways. Severe renal impairment data are limited.

Side effect profile in published trials#

The adverse event profile of tirzepatide is consistent with the GLP-1 class plus an incremental contribution from GIP agonism. Gastrointestinal symptoms dominate. Across SURPASS and SURMOUNT, nausea was reported by roughly 22 to 33 percent of participants depending on dose, diarrhoea by 17 to 22 percent, vomiting by 8 to 15 percent, and constipation by 6 to 11 percent. Most events were mild to moderate, transient, and concentrated in the first twelve weeks of titration. Discontinuation rates attributable to adverse events ranged from 4 to 7 percent at the highest doses.

Serious adverse events occurred at rates comparable to placebo in most trials. Acute pancreatitis occurred in under one percent of participants and did not differ statistically from placebo. Gallbladder events, including cholecystitis and cholelithiasis, were numerically elevated with tirzepatide, consistent with the broader weight-loss literature. Rapid weight loss of any kind increases gallstone risk.

The class carries a boxed warning in the United States for thyroid C-cell tumours. That warning is driven by rodent data with GLP-1 agonists showing medullary thyroid C-cell hyperplasia and C-cell tumours in two-year studies. The mechanism involves species-specific calcitonin handling that does not translate directly to humans. Human epidemiological data have not supported an increased risk, but the contraindication to use in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 is universal across the class.

Injection site reactions are mild. Most participants report minor erythema or induration that resolves within days. Severe reactions are rare.

Hypoglycaemia rates on tirzepatide monotherapy are low because the incretin effect is glucose-dependent. Rates rise when tirzepatide is combined with sulfonylureas or insulin, which is the same pattern seen with other GLP-1 agents.

Cardiovascular considerations and SURPASS-CVOT#

The SURPASS-4 data showed numerically lower major adverse cardiovascular event rates with tirzepatide than with insulin glargine over fifty-two weeks, but the trial was not powered as a dedicated cardiovascular outcomes trial. SURPASS-CVOT is the dedicated CVOT, enrolling roughly thirteen thousand participants with type 2 diabetes and established atherosclerotic cardiovascular disease. The comparator is dulaglutide, a confirmed GLP-1 agonist with known CV benefit, rather than placebo. The design makes SURPASS-CVOT a non-inferiority trial against an active CV-beneficial comparator, which is a higher bar than the usual placebo-controlled outcome trial.

Interim readouts have been reassuring but the final results are the definitive signal. Semaglutide already has SELECT, which demonstrated a twenty percent reduction in the composite CV endpoint in adults with overweight or obesity without diabetes. Tirzepatide is expected to produce comparable or larger CV benefit once SURPASS-CVOT reads out, but until that data arrives the class-level assumption is that tirzepatide at least matches GLP-1 mono agonists rather than that it exceeds them on cardiovascular endpoints.

Blood pressure reductions of 5 to 8 mmHg systolic have been reported across trials, larger than the reductions seen with semaglutide at the doses studied. Lipid improvements, including reductions in triglycerides of twenty to thirty percent and modest reductions in LDL cholesterol, have also been consistent.

Tirzepatide in the Canadian market: Mounjaro, Zepbound, and the research channel#

Health Canada approved tirzepatide under the brand name Mounjaro in November 2022 for the treatment of type 2 diabetes as an adjunct to diet and exercise. The formulation is a single-use prefilled autoinjector pen available in 2.5, 5, 7.5, 10, 12.5, and 15 milligram strengths, dosed weekly. Zepbound, the obesity indication formulation, followed in the trailing months. The approval mirrors the FDA label in indications and dosing.

Retail pricing in Canada sits at approximately 450 to 600 Canadian dollars per month out of pocket at most pharmacies, varying by dose and pharmacy chain. Provincial drug plan coverage is inconsistent. British Columbia PharmaCare, Ontario Drug Benefit, and provincial equivalents generally cover Mounjaro for type 2 diabetes under limited-use criteria, typically requiring prior failure of cheaper agents. Obesity coverage under public plans is narrower and largely unavailable. Private insurance coverage varies by employer and plan tier.

The access gap is the reason the research channel exists. A Canadian researcher studying incretin biology, a clinician running an off-label obesity programme, or an individual who cannot obtain coverage all share the same baseline problem: branded tirzepatide is expensive and intermittently available given periodic supply constraints. Research-grade tirzepatide, supplied as lyophilised powder in 10 or 30 milligram vials intended for reconstitution, fills that gap at a fraction of the per-milligram cost.

Health Canada's position on research-grade peptide supply is documented. Peptides sold without a Drug Identification Number and without therapeutic claims occupy a space governed by the Food and Drugs Act as unauthorised drugs. Enforcement has focused on suppliers and manufacturers making direct therapeutic claims rather than on the research-use-only trade. The College of Pharmacists of British Columbia and the Alberta College of Pharmacy have both issued statements in 2025 and 2026 describing compliance actions against unauthorised GLP-1 product sales. Canadian-source suppliers operating in the research channel have responded by tightening the research-use-only framing and by resisting the inclusion of therapeutic language anywhere in customer-facing materials. Buyers in this channel should read supplier documentation with that context in mind.

Importantly, the Health Canada approach does not permit pharmaceutical compounding of tirzepatide analogues in the way the United States did for much of 2023 and 2024. The FDA's shortage-driven compounding window, which supported a compounded tirzepatide market in the US, has no direct Canadian equivalent. Canadian buyers considering compounded tirzepatide from US sources should understand that importation of a compounded version of an approved drug carries separate regulatory issues.

Reconstitution for research use#

Tirzepatide arrives as a sterile lyophilised powder in a rubber-stoppered vial. Reconstitution with bacteriostatic water is the standard approach for research supply intended for repeated dosing over weeks. The bacteriostatic agent, typically 0.9 percent benzyl alcohol, inhibits bacterial growth in the reconstituted solution and extends usable life beyond what sterile water alone would support.

For a 10 mg vial, a common reconstitution target is 5 mg per mL. That is achieved by adding 2 mL of bacteriostatic water to the vial, producing a solution where 0.1 mL contains 500 micrograms. For a 30 mg vial, a 10 mg per mL concentration is typical, achieved by adding 3 mL of bacteriostatic water, producing a solution where 0.1 mL contains 1 milligram. Researchers tend to select concentrations that map cleanly to their intended dose step to simplify volume calculations on insulin syringes.

The mechanical process matters. The bacteriostatic water should be added slowly down the inner wall of the vial rather than injected directly onto the powder cake. Direct injection onto the cake can cause localised foaming and, in the case of some engineered peptides, transient denaturation. After the water is added, the vial should be swirled gently, never shaken. Tirzepatide is more tolerant of mechanical stress than some shorter peptides because of its length and secondary structure, but gentle handling remains the convention. Full dissolution should occur within five to fifteen minutes. The solution should be clear and colourless. Any turbidity or particulate matter at that point indicates a problem and the vial should not be used.

The reconstitution practice specifics are covered in depth in how to reconstitute peptides, the companion guide on this site. For a purchase file, the most useful section is the peptide reconstitution record quick-reference: it gives the receiving, solvent, concentration, label, storage, and exception-path fields that should travel with the tirzepatide lot record. If a study compares tirzepatide against another incretin material, add the research peptide solvent compatibility matrix so preservative, buffer, pH, vial-capacity, and vehicle-control assumptions are documented before the comparison becomes a data-quality problem.

Storage and stability#

Unreconstituted lyophilised tirzepatide is stable at refrigerated temperatures, typically 2 to 8 degrees Celsius, for the duration of a typical research supply cycle. Manufacturer shelf-life statements vary by source. Published stability data for synthetic tirzepatide suggest that the lyophilised form retains more than 95 percent purity for at least 24 months at refrigerated storage and is stable at minus 20 degrees Celsius for extended periods beyond that. Short excursions to room temperature during shipping do not meaningfully degrade the lyophilised material, which is why most suppliers ship without ice packs by default.

Reconstituted tirzepatide is less stable. The manufacturer label for branded tirzepatide allows thirty days of refrigerated use after first use of a multi-dose vial. Published stability data for synthetic tirzepatide in bacteriostatic water at 2 to 8 degrees Celsius show more than 95 percent purity retention at 28 days and more than 90 percent at 56 days under clean handling conditions. Reconstituted peptide should be protected from light, kept refrigerated when not in active use, and never frozen. Freeze-thaw cycles produce a sharp decline in purity and potency even after a single cycle.

Storage protocols for Canadian researchers working with tirzepatide should include a clearly labelled reconstitution date on every vial and a pre-committed disposal date twenty-eight days after reconstitution, or longer only if the research protocol explicitly allows extended-use stability studies on the material. If shipping, freezer, fridge, or bench exposure falls outside the accepted range, record it in the peptide temperature excursion log before interpreting downstream endpoints.

Research vial sizes: 10 mg versus 30 mg#

Research supply of tirzepatide typically comes in two vial sizes. A 10 mg vial produces enough reconstituted material for roughly four to six weeks of a low-to-mid dose study at typical research protocols, depending on dose schedule. A 30 mg vial produces three times the material at a per-milligram cost that is generally 30 to 50 percent lower than the 10 mg vial.

The choice between vial sizes depends on protocol duration and research discipline. A pilot study that runs four weeks and does not plan to extend should choose the 10 mg vial. Reconstituting a 30 mg vial and discarding unused material at 28 days is wasteful. A longer study that has already committed to twelve or more weeks should choose the 30 mg vial for cost efficiency but must also commit to the discipline of reconstituting, dating, refrigerating, and discarding on schedule.

Researchers also sometimes stock both sizes: 30 mg vials for planned protocol work and a small 10 mg stock for late-study dose adjustments or for running a parallel arm.

Purity considerations and what a COA should show#

Research-grade tirzepatide should come with a batch-specific certificate of analysis. The COA is the one document that translates supplier marketing into verifiable fact. Researchers sourcing from any vendor should read the COA closely before committing to a multi-batch supply relationship.

The core fields on a meaningful COA are purity measured by reversed-phase high-performance liquid chromatography, peptide content measured by amino acid analysis or nitrogen-based assay, identity confirmed by mass spectrometry, and residual solvent and heavy metals analyses. Purity by HPLC should be 99 percent or greater for research-grade tirzepatide. Peptide content should be at least 80 percent of net weight, with the balance made up primarily of trifluoroacetate and water. Mass spectrometry identity should confirm the molecular weight at 4,813 daltons plus or minus the acceptable tolerance.

Third-party testing strengthens the COA. A certificate issued by the supplier is worth reading, but a parallel certificate issued by an independent analytical laboratory carries more weight. Janoshik Analytical is the most widely recognised third-party peptide testing laboratory for the European and North American research market. Canadian researchers frequently look for Janoshik or a comparable independent lab attestation before placing a significant order.

More detail on reading COAs lives in the what is a COA companion guide.

Sourcing tirzepatide in Canada: what actually matters#

The Canadian research peptide supply landscape has evolved rapidly over the past two years. Several factors matter when evaluating a supplier for tirzepatide specifically.

Supplier continuity is the first filter. A supplier that has been operating for more than twelve months and has survived at least one period of enforcement attention is structurally more reliable than a new vendor. The peptide industry has a high churn rate at the supplier level. Enforcement actions by Health Canada, the FDA, and Chinese authorities have shut down both large and small vendors over the past three years. A supplier's operating history is a signal.

Per-batch COA availability is the second filter. A vendor that ships without batch-specific COAs, or that provides only a generic COA that does not reference the specific batch number on the vial received, is providing a document of limited value. The purpose of a batch-specific COA is to tie the analytical result to the physical material in hand.

Third-party test presence is the third filter. Self-reported COAs are better than no COA but weaker than independently-verified analytical results. A supplier that publishes third-party Janoshik Analytical reports or equivalent for recent batches provides meaningful verification.

Canadian shipping and fulfilment is the fourth consideration. Suppliers that ship from within Canada reduce customs risk and transit time. Suppliers that ship from China or from European warehouses introduce customs clearance uncertainty and potential for seizure. Canadian Border Services Agency published data in late 2025 indicated a marked increase in peptide shipment seizures from China, though the rate of seizure on any specific route remains difficult to predict. For Canadian researchers, a supplier with Canadian-domestic fulfilment is materially preferable.

Payment processing is the fifth practical factor. Mainstream credit card processors have tightened peptide-industry acceptance over the past eighteen months. Suppliers have moved toward Interac e-transfer, cryptocurrency, and international wire payments. Canadian buyers should expect that domestic suppliers will accept Interac e-transfer and possibly crypto, while international suppliers will typically accept crypto only. The payment method is downstream of supplier strategy rather than a reflection of legitimacy.

Customer service responsiveness and willingness to answer technical questions is the sixth factor that researchers consistently report mattering most in practice. A supplier willing to answer a direct question about batch COA details, storage conditions during shipping, or reconstitution recommendations is a different supplier from one that responds only to order inquiries.

The research peptides Canada buyer's guide covers supplier evaluation criteria in more depth. If the comparison question shifts from dual incretin biology into amylin-plus-incretin design, use the Cagrilintide research guide as the amylin-pathway bridge before reviewing supplier pages.

A mental model for the mechanism#

The dual-receptor mechanism is easier to hold in mind with a diagram than with prose. The diagram below simplifies the pathway to its structurally important nodes.

Rendering diagram...

The diagram skips some detail. It does not show the biased cAMP preference at GLP-1R relative to beta-arrestin, which is one of the proposed tolerability advantages. It does not show the direct vascular effects some studies have reported or the central CV autonomic effects under investigation. The diagram is a map for the core pathways, not a complete ontology.

Stack considerations#

Tirzepatide is occasionally combined with other compounds in research protocols. The most active area of interest is tirzepatide with amylin analogues, specifically cagrilintide. Cagrilintide is a long-acting amylin receptor agonist that produces satiety through a pathway distinct from incretin receptors. The combination, sometimes abbreviated CagriSema when paired with semaglutide, has been the subject of Phase 2 and Phase 3 trials with Novo Nordisk's product. Analogous combinations with tirzepatide have been explored in research settings. The theoretical rationale is that amylin signalling adds a complementary satiety pathway without overlapping the incretin system.

Combinations of tirzepatide with growth hormone secretagogues such as CJC-1295 or ipamorelin are occasionally discussed in research community contexts for body composition research, though published data on this specific combination are essentially non-existent. Researchers exploring such combinations should understand that the safety profile has not been characterised in controlled work and the interaction between GH axis stimulation and incretin signalling is not well studied.

Tirzepatide with AOD-9604 or MOTS-c for a more complete metabolic research stack is another combination occasionally reported in research-community protocols. Again, the controlled literature on such combinations is thin.

The default recommendation when running a research protocol with tirzepatide is to run it monotherapy unless the specific scientific question requires combination. Adding a second variable complicates attribution of any observed effect. A well-designed baseline single-agent tirzepatide protocol is usually a better starting point than a combination study.

Cost reality: branded versus research-grade per milligram#

Direct cost comparison helps put the research channel in perspective.

Branded tirzepatide in Canada at current pharmacy pricing runs approximately 450 to 600 Canadian dollars for a one-month supply of any dose. The dose does not meaningfully affect pharmacy pricing at the unit level. A one-month supply of 2.5 milligrams weekly delivers 10 total milligrams of active peptide. A one-month supply of 15 milligrams weekly delivers 60 total milligrams. The per-milligram cost therefore varies dramatically by dose: roughly 45 Canadian dollars per milligram at the 2.5 mg dose, down to roughly 8 Canadian dollars per milligram at the 15 mg dose.

Research-grade tirzepatide in Canada typically runs 120 to 180 Canadian dollars for a 30 milligram vial at current supplier pricing. That is roughly 4 to 6 Canadian dollars per milligram, a fraction of branded cost at any dose. The gap is larger at low dose equivalents and narrower at high dose equivalents, but the research channel is consistently cheaper per milligram of active peptide.

The cost gap is the economic reason the research channel exists. It is not primarily a matter of preference for unregulated supply. It is a response to a specific price structure imposed by clinical-channel distribution that is not tied to production costs.

Position relative to retatrutide#

Retatrutide is the triple agonist, adding glucagon receptor activity to the GIP and GLP-1 coverage that tirzepatide provides. Phase 2 data for retatrutide showed mean weight reductions of roughly twenty-four percent at forty-eight weeks on the highest dose, exceeding tirzepatide's seventy-two-week numbers. Retatrutide is not yet approved by any major regulator and is expected to receive first approval in 2026 or 2027.

For researchers choosing between tirzepatide and retatrutide, the decision is partly about the scientific question being asked. Tirzepatide has the mature evidence base and is the right compound for studies that need to land next to existing peer-reviewed literature. Retatrutide is the right compound for studies explicitly interested in glucagon receptor agonism or in exploring the upper bound of weight-loss effect size.

Practical considerations also differ. Tirzepatide is the more widely distributed compound in the research supply chain with more vendors, more batches tested, and more published stability data. Retatrutide supply is narrower and COA availability less consistent across suppliers. A study using retatrutide should budget additional effort on supplier verification.

The detailed discussion of the triple-agonist compound lives in the retatrutide research guide, which is the closest current companion to this tirzepatide overview. For quick triage, the three-way comparison separates trial-design caveats from receptor-count marketing, while the GLP-1 research compound comparison matrix keeps Retatrutide in the GLP-1/GIP/glucagon lane instead of treating it as simply a stronger Tirzepatide.

What the literature still does not tell us#

Three significant gaps remain in the tirzepatide evidence base and they are worth naming.

The first is long-term use beyond seventy-two weeks. SURMOUNT-4 provided some extension data, but sustained multi-year use patterns are still being characterised. Whether the metabolic gains hold across multi-year time horizons, whether tolerance develops, and whether late-emerging adverse events appear are open questions that real-world evidence will settle over the next five years.

The second is mechanism of the adipose-specific effects. The SURPASS-3 MRI substudy and later imaging work have shown that tirzepatide produces reductions in liver fat and visceral adipose tissue that exceed what matched weight loss from other means would predict. The mechanism is not fully characterised. Adipocyte GIP receptor engagement is the leading hypothesis but controlled human metabolic studies to confirm the specific adipose pathway remain limited.

The third is comparative cardiovascular benefit. SELECT established semaglutide's CV benefit in adults with obesity. SURPASS-CVOT will establish tirzepatide's, but until the final readout the class-level assumption that benefits extend to tirzepatide is inference rather than direct evidence.

Frequently asked research questions#

Summary for Canadian researchers#

Tirzepatide represents the current frontier of approved incretin therapy in Canada. The molecule's dual GIP and GLP-1 agonism produces weight and glycaemic effects that exceed mono GLP-1 agonism in direct head-to-head comparison. The safety profile is dominated by transient gastrointestinal events during titration and is otherwise consistent with the broader GLP-1 class. Canadian approval as Mounjaro for type 2 diabetes and Zepbound for obesity gives the compound a clear clinical pathway, but cost and coverage realities sustain strong demand in the parallel research channel.

For Canadian researchers selecting tirzepatide for non-clinical work, the practical priorities are supplier continuity, per-batch COA availability, independent third-party testing, reconstitution discipline with proper dating and disposal protocols, and cold-chain handling consistent with published stability data. These are the variables that determine whether a study produces interpretable results on a compound that is otherwise well characterised in the literature.

The companion guides on this site cover adjacent topics in more depth. How to reconstitute peptides walks through the mechanical process. What is a COA explains how to read a certificate of analysis. The research peptides Canada buyer's guide covers supplier evaluation criteria. Semaglutide vs tirzepatide puts the head-to-head comparison in one place. The GLP-1 research compound comparison matrix adds the broader receptor-lane worksheet for deciding when Tirzepatide should be compared against Semaglutide, Retatrutide, Cagrilintide, or excluded non-incretin metabolic materials without drifting into personal-use claims. Best peptides for weight loss in Canada frames the wider category.